Economic Implications of Lipid-Lowering Trials: Current Considerations in Selecting a Statin

American Journal of Cardiology

Volumn 82, Issue 6 SUPPL. 1, 1998, Pages

  Farmer, John A ^a,b,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b BEN TAUB GENERAL HOSPITAL   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPID;

BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY ARTERY ATHEROSCLEROSIS; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; REVIEW; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; CHOLESTEROL; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; COST-BENEFIT ANALYSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; TREATMENT OUTCOME;

EID: 0032563770     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00594-3     Document Type: Article

References (21)

1. Gibaldi M, Kradjan W. Treating elevated cholesterol levels: the great satan in perspective. J Clin Pharmacol 1996:36:189-197.
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995:333:1301-1307.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994:344:1383-1389.
4. National Health and Nutrition Examination Survey III (NHANES III). National Center for Health Statistics, Centers for Disease Control and Prevention, 1994 (unpublished).
5. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994:89:1329-1445.
6. Herd JA, Ballantyne CM, Farmer JA, Ferguson JJ III, Jones PH, West MS, Gould KL, Gotto AM Jr. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997:80:278-286.
7. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996:335:1001-1009.
8. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr, for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
9. Pedersen TR, Tobert JA. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal. Drug Saf 1996;14:11-24.
10. American Heart Association. Heart and Stroke Facts Statistical Update 1997. Dallas: American Heart Association, 1997.
11. Jacobson TA, Marchman K. Improving the cost-effectiveness of lipid-lowering therapy in coronary prevention. In: Gotto AM, Lenfant C, Catapano AL, Paoletti R, eds. Multiple Risk Factors in Cardiovascular Disease: Strategies of Prevention of Coronary Heart Disease, Cardiac Failure, and Stroke. Dordrecht: Kluwer Academic Publishers, 1997.
12. Johanneson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H, for the Scandinavian Simvastatin Survival Study Group. Cost-effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997;336:332-336.
13. Shepherd J, for the West of Scotland Coronary Prevention Study Economic Analysis Group. The cost-effectiveness of preventing initial coronary events with pravastatin. Results of the West of Scotland Coronary Prevention Study economic analysis. (Abstr.) J Am Coll Cardiol 1997;29(suppl A):188A.
14. Ramsay LE, Haq IU, Jackson PR, Yeo WW, Pickin DM, Payne JN. Targeting lipid lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Lancet 1996;348:387-388.
15. Jacobson TA. Improving health outcomes without increasing costs: maximizing the full potential of lipid reduction therapy in the primary and secondary prevention of coronary heart disease. Curr Opin Lipidol 1997;8:369-374.
16. Martens LL, Rutten FFH, Erkelens W, Ascoops CAPL. Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in The Netherlands. Am J Cardiol 1990;65(suppl):27F-32F.
17. Schulman KA, Kinosian B, Jacobson TA, Glick H, Willian MK, Koffer H, Eisenberg JM. Reducing high blood cholesterol level with drugs: cost-effectiveness of pharmacologic management. JAMA 1990;264:3025-3033.
18. Perreault S, Hamilton VH, Lavoie F, Grover S. A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia. Cardiovasc Drugs Ther 1997;10:787-794.
19. Sempos CT, Cleeman JI, Carroll MD, Johnson CL, Bachorik PS, Gordon DJ, Burt VL, Briefel RR, Brown CD, Lippel K, Rifkind BM. Prevalence of high blood cholesterol among US adults. An update based on guidelines from the Second Report of the National Cholesterol Education Program Adult Treatment Panel. JAMA 1993;269:3009-3104.
20. Curtiss FR. Lessons learned from projects in disease management in ambulatory care. Am J Health-Syst Pharm 1997;54:2217-2229.
21. Pettita A, Ward RE, Anandan JV, Beis SJ, Johnson AM. The cost-effectiveness impact of a preferred agent HMG-CoA reductase inhibitor policy in a managed care population. J Managed Care Pharm 1997;3:548-553.